A score to predict short-term risk of COPD exacerbations (SCOPEX)

International Journal of COPD

Volumn 10, Issue , 2015, Pages 201-209

  Make, Barry J ^a   Eriksson, Göran ^b   Calverley, Peter M ^c   Jenkins, Christine R ^d   Postma, Dirkje S ^e   Peterson, Stefan ^f   Östlund, Ollie ^g   Anzueto, Antonio ^h  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^d GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f StatMind AB   (Sweden)

^g UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; Exacerbation; Inhaled corticosteroids; Model; Predictor

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALBUTAMOL; THEOPHYLLINE; BUDESONIDE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FORMOTEROL FUMARATE; GLUCOCORTICOID;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG USE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HIGH RISK PATIENT; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL VARIABLE; PREDICTION; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY TRACT DISEASE ASSESSMENT; RISK ASSESSMENT; RISK REDUCTION; SCORE TO PREDICT SHORT TERM RISK OF COPD EXACERBATION; SCORING SYSTEM; STATISTICAL MODEL; AGED; AREA UNDER THE CURVE; COMBINATION DRUG THERAPY; COMPLICATION; DECISION SUPPORT SYSTEM; DISEASE COURSE; DRUG COMBINATION; DRUG EFFECTS; LUNG; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; TIME FACTOR; TREATMENT OUTCOME; VITAL CAPACITY;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; ALBUTEROL; AREA UNDER CURVE; BRONCHODILATOR AGENTS; BUDESONIDE; DECISION SUPPORT TECHNIQUES; DISEASE PROGRESSION; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; FORMOTEROL FUMARATE; GLUCOCORTICOIDS; HUMANS; LOGISTIC MODELS; LUNG; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84922011429     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S69589     Document Type: Article

References (34)

1. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418-1422.
2. Quint JK, Baghai-Ravary R, Donaldson GC, Wedzicha JA. Relationship between depression and exacerbations in COPD. Eur Respir J. 2008;32(1):53-60.
3. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-852.
4. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. Chest. 2001;119(2):344-352.
5. Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ. Lung function impairment, COPD hospitalisations and subsequent mortality. Thorax. 2011;66(7):585-590.
6. McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest. 2007;132(6):1748-1755.
7. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925-931.
8. Global Initiative for Chronic Obstructive Lung Disease (GOLD) [webpage on the Internet]. Global Strategy for the Diagnosis, Management and Prevention of COPD 2010. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed August 24, 2012.
9. Postma D, Anzueto A, Calverley P, et al. A new perspective on optimal care for patients with COPD. Prim Care Respir J. 2011;20(2):205-209.
10. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128-1138.
11. Jenkins CR, Celli B, Anderson JA, et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. Eur Respir J. 2012;39(1):38-45.
12. Donaldson GC, Wedzicha JA. COPD exacerbations. 1: Epidemiology. Thorax. 2006;61(2):164-168.
13. Kim V, Han MK, Vance GB, et al; COPDGene Investigators. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest. 2011;140(3):626-633.
14. Xu W, Collet JP, Shapiro S, et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med. 2008;178(9):913-920.
15. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14): 1975-2000.
16. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549-565.
17. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012;106(2):257-268.
18. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85 Suppl B:25-31; discussion 33-27.
19. Leidy NK, Schmier JK, Jones MK, Lloyd J, Rocchiccioli K. Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale. Respir Med. 2003;97 Suppl A:S59-S70.
20. Calverley P, Pauwels RA, Jones PW, Anderson JA, Vestbos J. The severity of airways obstruction as a determinant of treatment response in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(3):209-218.
21. Miravitlles M, Guerrero T, Mayordomo C, Sánchez-Agudo L, Nicolau F, Segú JL. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration. 2000;67(5):495-501.
22. Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indexes for exacerbations and hospitalizations due to COPD. Chest. 2007;131(1):20-28.
23. Rowe BH, Villa-Roel C, Guttman A, et al. Predictors of hospital admission for chronic obstructive pulmonary disease exacerbations in Canadian emergency departments. Acad Emerg Med. 2009;16(4): 316-324.
24. Johannessen A, Omenaas ER, Bakke PS, Gulsvik A. Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax. 2005;60(10): 842-847.
25. Postma DS, Anzueto AR, Calverley PM, et al. Identifying COPD heterogeneity by easily measurable characteristics. Am J Respir Crit Care Med. 2011;183:A1018.
26. de Torres JP, Casanova C, Hernández C, Abreu J, Aguirre-Jaime A, Celli BR. Gender and COPD in patients attending a pulmonary clinic. Chest. 2005;128(4):2012-2016.
27. Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159(1):158-164.
28. Briggs A, Spencer M, Wang H, Mannino D, Sin DD. Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Arch Intern Med. 2008;168(1): 71-79.
29. Schembri S, Anderson W, Morant S, et al. A predictive model of hospitalisation and death from chronic obstructive pulmonary disease. Respir Med. 2009;103(10):1461-1467.
30. Laurin C, Moullec G, Bacon SL, Lavoie KL. Impact of anxiety and depression on chronic obstructive pulmonary disease exacerbation risk. Am J Respir Crit Care Med. 2012;185(9):918-923.
31. Atlantis E, Fahey P, Cochrane B, Smith S. Bidirectional associations between clinically relevant depression or anxiety and COPD: a systematic review and meta-analysis. Chest. 2013;144(3):766-777.
32. Hanania NA, Mullerova H, Locantore NW, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study investigators. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med. 2011;183(5):604-611.
33. Wells JM, Washko GR, Han MK, et al; COPDGene Investigators; ECLIPSE Study Investigators. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med. 2012;367(10):913-921.
34. Han MK, Kazerooni EA, Lynch DA, et al; COPDGene Investigators. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology. 2011;261(1): 274-282.